reports
Madrigal Pharmaceuticals Inc: 2 directors
Two Directors at Madrigal Pharmaceuticals Inc bought/sold 173,299 shares at between 373.732USD and 400.178USD. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compan...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2025 to 11 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in acc...
Madrigal Receives European Commission Approval for Rezdiffra™ (resmeti...
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 MAESTRO-NASH trial demonstrating Rezdiffra reduced fibrosis, resolved MASH and improved key noninvasive testsRezdiffra is already included in European MASH treatment guidelines as a first-line treatmentMadrigal is planning for its first European launch in German...
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th ...
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT. The presentation will be webcast live and may be accessed or by visiting Madrigal’s Investor Relations Events and Presentations . A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL)...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2025 to 26 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in acco...
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results...
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, 2045Announced global licensing agreement for an oral GLP-1 development candidate In July, secured up to $500 million in senior secured credit to advance pipeline Presented compelling two-year F4c data at EASL Congress; provides estimates for U.S. F4c MASH patient population Received positive CHMP...
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreemen...
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GLP-1, SYH2086, offers potential for a best-in-class MASH treatment in a once-a-day, well-tolerated pill CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it...
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Resu...
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its second-quarter 2025 financial results on Wednesday, Aug. 5, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time t...
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit...
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility$350 million initial term loan funded at close and up to an additional $150 million available through 2027Agreement also provides for the possibility of additional incremental facilities of up to $250 million of credit to support further strategic pipeline expansion CONSHOHOCKEN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, ...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 1, 2025 and July 15, 2025 to a total of 30 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Com...
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent...
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom) • Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance covering the FDA-approved use ...
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) fo...
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected in August 2025; if approved, resmetirom will be the first medication for people living with MASH in the E.U. CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for met...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2025 to 36 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2023 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accor...
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Gold...
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT. The presentation will be webcast live and may be accessed or by visiting Madrigal’s Investor Relations Events and Presentations . A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, I...
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmeti...
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk categories by year twoPatients achieved a mean 6.7 kPa reduction in liver stiffness, which was statistically significant compared to baseline CONSH...
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results ...
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marke...
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Com...
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced six presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands. Madrigal will share detailed two-year data from the open-label compen...
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Resul...
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to revi...
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. ...
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer Dr. Taub’s pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that Rebecca Taub, M.D., the company's founder, Chief Med...
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn (“Jackie”) Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of Directors, stated, ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.